India’s Ultrahuman secures $11.3m debt to expand globally

Ultrahuman, a Bengaluru-based wearable tech startup, has secured 100 crore rupee (US$11.3 million) in venture debt from Alteria Capital to support its expansion into Canada, Mexico, and Australia.

The company is currently involved in a patent dispute in the US with Oura over its smart ring, but said the case does not affect its other products, such as its sleep monitor, continuous glucose monitor, and blood testing services.

Blood testing now accounts for 5% of Ultrahuman’s revenue and is growing in India, the US, and the United Arab Emirates.

Ultrahuman reported that existing inventory in the US should prevent short-term revenue impact from the patent dispute.

The firm is also working on a new ring model with updated features.

Ultrahuman expects to close a larger funding round soon and is projecting revenue of over 1,000 crore rupee (US$112.8 million) in FY26.

🔗 Source: YourStory

🧠 Food for thought

Implications, context, and why it matters.

Patent dispute context includes International Trade Commission orders; revenue assurances remain

Ultrahuman faces two U.S. patent suits, filed in September 2023 in the Eastern District of Texas 1 and in September 2025 covering patents including US12222759 2.
Public dockets list no district-court preliminary injunctions. Press reports say the ITC barred Ring Air sales in the U.S. 3.
Management says existing inventory will cover near-term revenue, while press reports describe ITC rulings that bar U.S. Ring Air sales 3. The September 2025 Texas suit is early, with a scheduling conference set for November 24, 2025, and no merits rulings yet 2.
The FY26 revenue target of over Rs 1,000 crore leans on steady U.S. sales. Investors need clarity on ITC scope, order duration, plus district-court timing to assess disruption and the planned funding round.

Geographic expansion creates demand for compliance service providers

Canada’s Medical Devices Regulations set Classes I to IV for smart rings and require Class II to IV licensing plus labeling plus quality management certification, with consultancies bundling steps with Health Canada submission guidance (Health Canada is the federal health regulator) 4 5.
Blood testing that expands to India, the U.S., and the United Arab Emirates needs privacy compliance by jurisdiction plus clinical certifications. The U.S. uses the Health Insurance Portability and Accountability Act (HIPAA), while the UAE applies local rules.
Mexico’s Federal Commission for the Protection against Sanitary Risk and Australia’s Therapeutic Goods Administration run distinct device frameworks that create opportunities for specialists 6.